Moia R, Patriarca A, Deambrogi C, Rasi S, Favini C, Kodipad AA, et al. An update on: molecular genetics of high-risk chronic lymphocytic leukemia. Expert Rev Hematol. 2020;13(2):109–16.

Article  CAS  PubMed  Google Scholar 

Mulligan SP, Tam CS. Chronic lymphocytic leukemia: diagnosis and clinical staging. Advances in the treatment of B-cell chronic lymphocytic leukemia; 2012. p. 6–15.

Mukkamalla SKR, Taneja A, Malipeddi D, Master SR. Chronic Lymphocytic Leukemia. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2021, StatPearls Publishing LLC.; 2021.

Eichhorst B, Robak T, Montserrat E, Ghia P, Niemann CU, Kater AP, et al. Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(1):23–33.

Article  CAS  PubMed  Google Scholar 

Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745–60.

Article  CAS  PubMed  Google Scholar 

WHO. Chronic lymphocytic leukemia. 2014 Review of Cancer Medicines on the WHO List of Essential Medicines. 2014.

Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101–10.

Article  CAS  PubMed  Google Scholar 

Hallek M, Al-Sawaf O. Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. Am J Hematol. 2021;96(12):1679–705.

Article  PubMed  Google Scholar 

Lachaine J, Beauchemin C, Guinan K, Thebault P, Aw A, Banerji V, et al. Impact of oral targeted therapy on the economic burden of chronic lymphocytic leukemia in Canada. Curr Oncol. 2021;28(1):332–45.

Article  PubMed  PubMed Central  Google Scholar 

Montserrat E, Bauman T, Delgado J. Present and future of personalized medicine in CLL. Best Pract Res Clin Haematol. 2016;29(1):100–10.

Article  PubMed  Google Scholar 

Vellekoop H, Huygens S, Versteegh M, Szilberhorn L, Zelei T, Nagy B, et al. Guidance for the harmonisation and improvement of economic evaluations of personalised medicine. Pharmacoeconomics. 2021;39(7):771–88.

Article  PubMed  PubMed Central  Google Scholar 

Miller JD, Foley KA, Russell MW. Current challenges in health economic modeling of cancer therapies: a research inquiry. Am Health Drug Benefits. 2014;7(3):153–62.

PubMed  PubMed Central  Google Scholar 

Bullement A, Cranmer HL, Shields GE. A review of recent decision-analytic models used to evaluate the economic value of cancer treatments. Appl Health Econ Health Policy. 2019;17(6):771–80.

Article  PubMed  PubMed Central  Google Scholar 

Kasteng F, Sobocki P, Svedman C, Lundkvist J. Economic evaluations of leukemia: a review of the literature. Int J Technol Assess Health Care. 2007;23(1):43–53.

Article  PubMed  Google Scholar 

Marsh K, Xu P, Orfanos P, Gordon J, Griebsch I. Model-based cost-effectiveness analyses for the treatment of chronic lymphocytic leukaemia: a review of methods to model disease outcomes and estimate utility. Pharmacoeconomics. 2014;32(10):981–93.

Article  PubMed  Google Scholar 

Harkins RA, Patel SP, Flowers CR. Cost-effectiveness of new targeted agents in the treatment of chronic lymphocytic leukemia. Cancer J (United States). 2019;25(6):418–27.

Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71.

Article  PubMed  PubMed Central  Google Scholar 

Adarkwah CC, van Gils PF, Hiligsmann M, Evers SM. Risk of bias in model-based economic evaluations: the ECOBIAS checklist. Expert Rev Pharmacoecon Outcomes Res. 2016;16(4):513–23.

Article  PubMed  Google Scholar 

Buchanan J, Wordsworth S, Clifford R, Robbe P, Taylor JC, Schuh A, et al. Using genomic information to guide ibrutinib treatment decisions in chronic lymphocytic leukaemia: a cost-effectiveness analysis. Pharmacoeconomics. 2017;35(8):845–58.

Article  PubMed  PubMed Central  Google Scholar 

Patel KK, Isufi I, Kothari S, Davidoff AJ, Gross CP, Huntington SF. Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia. Blood. 2020;136(17):1946–55.

Article  PubMed  Google Scholar 

Chen Q, Jain N, Ayer T, Wierda WG, Flowers CR, O’Brien SM, et al. Economic burden of chronic lymphocytic leukemia in the era of oral targeted therapies in the United States. J Clin Oncol. 2017;35(2):166–74.

Article  CAS  PubMed  Google Scholar 

Kongnakorn T, Sterchele JA, Salvador CG, Getsios D, Mwamburi M. Economic implications of using bendamustine, alemtuzumab, or chlorambucil as a first-line therapy for chronic lymphocytic leukemia in the US: a cost-effectiveness analysis. Clinicoecon Outcomes Res. 2014;6:141–9.

Article  PubMed  PubMed Central  Google Scholar 

Scott WG, Scott HM. Economic evaluation of third-line treatment with alemtuzumab for chronic lymphocytic leukaemia. Clin Drug Investig. 2007;27(11):755–64.

Article  CAS  PubMed  Google Scholar 

Danese MD, Reyes CM, Gleeson ML, Halperin M, Skettino SL, Mikhael J. Estimating the population benefits and costs of rituximab therapy in the United States from 1998 to 2013 using real-world data. Med Care. 2016;54(4):343–9.

Article  PubMed  PubMed Central  Google Scholar 

Weeks JC, Tierney MR, Weinstein MC. Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. N Engl J Med. 1991;325(2):81–6.

Article  CAS  PubMed  Google Scholar 

Adena M, Houltram J, Mulligan SP, Todd C, Malanos G. Modelling the cost effectiveness of rituximab in chronic lymphocytic leukaemia in first-line therapy and following relapse. Pharmacoeconomics. 2014;32(2):193–207.

Article  PubMed  Google Scholar 

Hornberger J, Reyes C, Shewade A, Lerner S, Friedmann M, Han L, et al. Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for the treatment of previously untreated chronic lymphocytic leukemia. Leuk Lymphoma. 2012;53(2):225–34.

Article  CAS  PubMed  Google Scholar 

Howard DR, Munir T, McParland L, Rawstron AC, Chalmers A, Gregory WM, et al. Clinical effectiveness and cost-effectiveness results from the randomised, phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the attenuated dose rituximab with chemotherapy in chronic lymphocytic leukaemia (ARCTIC) trial. Health Technol Assess. 2017;21(28):vii–373.

Article  Google Scholar 

Main C, Pitt M, Moxham T, Stein K. The clinical effectiveness and cost-effectiveness of rituximab for the first-line treatment of chronic lymphocytic leukaemia: an evidence review of the submission from Roche. Health Technol Assess. 2010;14(Suppl. 2):27–32.

Article  CAS  PubMed  Google Scholar 

Mandrik O, Corro Ramos I, Knies S, Al M, Severens JL. Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia in Ukraine. Cancer Manag Res. 2015;7:279–89.

Article  PubMed  PubMed Central  Google Scholar 

Müller D, Fischer K, Kaiser P, Eichhorst B, Walshe R, Reiser M, et al. Cost-effectiveness of rituximab in addition to fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemia. Leuk Lymphoma. 2016;57(5):1130–9.

Article  PubMed  Google Scholar 

Becker U, Briggs AH, Moreno SG, Ray JA, Ngo P, Samanta K. Cost-effectiveness model for chemoimmunotherapy options in patients with previously untreated chronic lymphocytic leukemia unsuitable for full-dose fludarabine-based therapy. Value Health. 2016;19(4):374–82.

Article  PubMed  Google Scholar 

Blommestein HM, de Groot S, Aarts MJ, Vemer P, de Vries R, van Abeelen AF, et al. Cost-effectiveness of obinutuzumab for chronic lymphocytic leukaemia in The Netherlands. Leuk Res. 2016;50:37–45.

Article  PubMed  Google Scholar 

Casado LF, Burgos A, González-Haba E, Loscertales J, Krivasi T, Orofino J, et al. Economic evaluation of obinutuzumab in combination with chlorambucil in first-line treatment of patients with chronic lymphocytic leukemia in Spain. Clinicoecon Outcomes Res. 2016;8:475–84.

Article  PubMed  PubMed Central  Google Scholar 

Paquete AT, Miguel LS, Becker U, Pereira C, Pinto CG. Cost-effectiveness analysis of obinutuzumab for previously untreated chronic lymphocytic leukaemia in portuguese patients who are unsuitable for full-dose fludarabine-based therapy. Appl Health Econ Health Policy. 2017;15(4):501–12.

Article  PubMed  Google Scholar 

Sinha R, Redekop WK. Cost-effectiveness of ibrutinib compared with obinutuzumab with chlorambucil in untreated chronic lymphocytic leukemia patients with comorbidities in the United Kingdom. Clin Lymphoma Myeloma Leuk. 2018;18(2):e131–42.

Article  PubMed  Google Scholar 

Soini E, Hautala A, Poikonen E, Becker U, Kyttälä M, Martikainen J. Cost-effectiveness of first-line chronic lymphocytic leukemia treatments when full-dose fludarabine is unsuitable. Clin Ther. 2016;38(4):889-904.e14.

Article  PubMed  Google Scholar 

Barnes JI, Divi V, Begaye A, Wong R, Coutre S, Owens DK, et al. Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p. Blood Adv. 2018;2(15):1946–56.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dervaux B, Lenne X, Theis D, D’Alche-Gautier M-J, Rufat P, Cazin B, et al. Cost effectiveness of oral fludarabine in chronic lymphocytic leukaemia: the French case. J Med Econ. 2007;10(4):339–54.

Article  Google Scholar 

Herring W, Pearson I, Purser M, Nakhaipour HR, Haiderali A, Wolowacz S, et al. Cost effectiveness of ofatumumab plus chl